Yervoy (ipilimumab) - BMS
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Keytruda (pembrolizumab) - Merck (MSD)
NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma (clinicaltrials.gov) - Oct 1, 2026 - P2 | N=55 | Recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Not yet recruiting ➔ Recruiting 
Enrollment open • Cutaneous Melanoma • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor
http://clinicaltrials.gov/ct2/show/NCT07740941
 
Oct 1, 2026
 
Prev Next